Recursion and Roche/Genentech run a multi-year collaboration using Recursion OS and Maps of Biology in neuroscience and oncology.
The collaboration combines Recursion OS and Maps of Biology with Roche and Genentech single-cell perturbation data, with up to 40 programs possible. The partners page lists $150M upfront and potential milestones above $300M per program plus tiered royalties.
Recursion is a US techbio company running Recursion OS and large biological maps for drug discovery with pharma partners including Roche, Genentech, Sanofi and Bayer.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Published by Recursion on its own site — read the original case study on recursion.com ↗
Note: Partners overview page, not a dedicated case study.
Related use cases
- 01Recursion and Sanofi collaborate to discover and advance up to 15 novel targets in oncology and immunology.
- 02Recursion and Bayer collaborate on up to seven precision oncology programs.
- 03OpenAI's dedicated healthcare vertical page/launch post.
- 04Frontier reasoning model built for biology, drug discovery and translational medicine; named qualified customers include Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.
- 05follow-up update to the life-sciences model.
- 06"How Amgen uses GPT-5": Amgen applies GPT-5/frontier models to help accelerate delivery of potential new therapies; found GPT-5 met scientific-accuracy standards.